这款革命性明星抗癌药NKTR-214,其和PD-1抑制剂联用,可大幅度提高PD-1抑制剂的有效率,甚至连PD-L1阴性也有效,给无数癌症患者带来希望。
参考来源:
Diab A. Pivot-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma, renal cell carcinoma and non-small cell lung cancer. Presented at: SITC 32nd Annual Meeting; National Harbor, MD; November 8-12, 2017. Session 207.7
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。